Contrasting PAVmed (NASDAQ:PAVM) & Integer (NYSE:ITGR)

Integer (NYSE:ITGR) and PAVmed (NASDAQ:PAVM) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Earnings and Valuation

This table compares Integer and PAVmed”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85 billion	1.59	$102.81 million	$2.87	29.77
PAVmed	$2.99 million	2.84	$39.79 million	($17.12)	-0.51

Integer has higher revenue and earnings than PAVmed. PAVmed is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

99.3% of Integer shares are held by institutional investors. Comparatively, 19.9% of PAVmed shares are held by institutional investors. 2.2% of Integer shares are held by insiders. Comparatively, 5.8% of PAVmed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Integer and PAVmed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Integer	5.55%	13.26%	6.69%
PAVmed	10,672.42%	-754.98%	-19.87%

Analyst Ratings

This is a summary of recent recommendations and price targets for Integer and PAVmed, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	0	6	4	0	2.40
PAVmed	1	1	1	0	2.00

Integer presently has a consensus target price of $102.00, suggesting a potential upside of 19.36%. PAVmed has a consensus target price of $510.00, suggesting a potential upside of 5,782.35%. Given PAVmed’s higher probable upside, analysts clearly believe PAVmed is more favorable than Integer.

Risk and Volatility

Integer has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, PAVmed has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.

Summary

Integer beats PAVmed on 9 of the 14 factors compared between the two stocks.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.

About PAVmed

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.